AccuImage names Taylor as new CEO
AccuImage names Taylor as new CEORobert Taylor has been appointed CEO of AccuImage, a South San Francisco, CA-based developer of 3-D and 4-D post-processing and connectivity software for PACS and other medical imaging applications. Taylor,
AccuImage names Taylor as new CEO
Robert Taylor has been appointed CEO of AccuImage, a South San Francisco, CA-based developer of 3-D and 4-D post-processing and connectivity software for PACS and other medical imaging applications. Taylor, previously COO of AccuImage, replaces Allen Poirson, who resigned from the company.
AccuImage expects Taylors appointment to help expedite AccuImages current product development efforts, which include AccuView, a 3-D workstation, and eStation 3D, a Web-based workstation for PACS and teleradiology. Taylor will be responsible for moving AccuView into the marketplace and overseeing final development of eStation 3D, according to Douglas Boyd, chairman of AccuImage. Both products incorporate AccuImages proprietary software platform, which provides review and analysis tools for CT, MR, and ultrasound imaging and enables the transfer of medical images across the Internet and hospital intranets.
- Search again
- Homepage
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
